Work

Cerebral Small Vessel Disease as a Driver of Mixed Dementia: Mechanisms, Biomarkers, and Therapeutic Implications

Year: 2026
Type: article
Abstract: “Mixed dementia” refers to dementia in which more than one neuropathological process contributes, most often Alzheimer’s disease (AD) together with at least one other pathology. Far from being an exception, it is the most common substrate of dementia in older adults. Of the pathologies that accompany AD, cerebral small vessel disease (cSVD) is the most frequent and arguably the most consequential because it is the one with the strongest evidence for modifiability. In this narrative review, we argue that cSVD does not simply co-occur with AD but helps determine whether subclinical pathology becomes clinically overt dementia. We searched PubMed from 1984 onward with a structured Boolean strategy, supplemented by citation searching, reported the search and selection using items of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement, and included 83 sources spanning autopsy cohorts, consensus statements, randomized trials, meta-analyses, and mechanistic studies. We first examine why clinical, imaging, and neuropathological classifications of mixed dementia so often disagree. We then review autopsy and population evidence on arteriolosclerosis, microinfarcts, and cerebral amyloid angiopathy (CAA); in pooled community-based autopsy data, 91% of decedents aged 80 years or older had more than one dementia-associated neuropathology, and vascular injury lowers the burden of Alzheimer pathology needed to produce dementia. We examine the leading mechanisms proposed to explain this relationship (endothelial and blood-brain barrier (BBB) failure, chronic hypoperfusion, impaired perivascular clearance, neuroinflammation, and oligodendrocyte injury) and consider how each might interact with amyloid-beta and tau. We then turn to the imaging and fluid biomarkers used to separate vascular from degenerative disease during life and argue that these tools are asymmetric: molecularly precise for AD, largely descriptive for cSVD. Finally, we review the treatment evidence, including blood pressure lowering, endothelial-targeted therapy, and multidomain lifestyle intervention, and consider what cSVD means for eligibility, safety, and expected benefit from anti-amyloid monoclonal antibodies. We conclude that the field should move beyond an either/or model of dementia and instead measure and treat vascular disease in every patient with cognitive impairment.
Source: Cureus
Language: English
Field: Medicine
Open Access status: diamond
OpenAlex ID: W7234360741
FWCI:
Cites: 85
Cited by:
Related to: 10